Agios Pharmaceuticals (AGIO) FY2025 10-K Risk Factors: 9 New, 8 Dropped

What the changes say

Agios added new risks covering U.S. tariffs, clinical trial disruptions, and regulatory exclusivity challenges for its drug pipeline.

What changed since the prior 10-K

New

NewRisks Related to the Discovery, Development, and Commercialization of our Products and Product Candidates
Ongoing or unanticipated geopolitical events in countries where we may to have clinical trial sites could also negatively impact our ability to initiate, enroll and retain patients in, and conduct clinical trials
Geopolitical events in clinical trial locations could delay patient enrollment and increase trial costs.
NewRisks Related to the Discovery, Development, and Commercialization of our Products and Product Candidates
The FDA may not approve an ANDA or 505(b)(2) NDA until any applicable period of regulatory exclusivity for the reference-listed drug has expired, subject to certain exceptions
Generic competitors might launch via ANDA or 505(b)(2) NDAs before regulatory exclusivity expires, impacting future revenues.
NewRisks Related to the Discovery, Development, and Commercialization of our Products and Product Candidates
eliminated entirely. We cannot guarantee that the measures we have taken to date, and actions we may take in the future, will be sufficient to prevent any cyber-attacks or security breaches
NewRisks Related to Our Financial Position
product candidates, and unanticipated changes in applicable laws and regulations that may adversely affect the rare disease business
Focusing heavily on rare disease markets makes financial performance more volatile and susceptible to changing market conditions.
NewRisks Related to Regulatory Approval of Our Product Candidates and Other Legal Compliance Matters
We may not be successful in obtaining FDA or EMA approval of our product candidates on a timely basis, or ever. We have limited experience in filing and supporting the applications necessary to gain marketing approvals and expect to rely on third-party CROs to assist us in this process
Financial relationships between principal investigators and the company could create conflicts of interest, jeopardizing trial data integrity and FDA approval.
NewRisks Related to Regulatory Approval of Our Product Candidates and Other Legal Compliance Matters
Fast track designation, priority review designation, PRIME designation or other expedited review designations or vouchers may not actually lead to a faster development or regulatory review or approval process, nor does it ensure approval of the product candidate
Expedited review designations like Fast Track or PRIME may not actually lead to faster development or guaranteed approval.
NewRisks Related to Regulatory Approval of Our Product Candidates and Other Legal Compliance Matters
We do not know if, when, or how the FDA or Congress may reevaluate or change the orphan drug regulations and policies in the future, and it is uncertain how any changes might affect our business or if we will be adversely impacted
Orphan drug regulations and post-approval compliance requirements are subject to future changes and strict enforcement penalties.
NewRisks Related to Regulatory Approval of Our Product Candidates and Other Legal Compliance Matters
Accordingly, if any of the foregoing developments and others impact the ability of the FDA to provide us with guidance or delay the FDA’s review and processing of our regulatory submissions, our business would be negatively impacted
Interactions with healthcare providers and payors expose the company to anti-kickback and fraud and abuse laws regarding PYRUKYND and AQVESME.
NewRisks Related to Regulatory Approval of Our Product Candidates and Other Legal Compliance Matters
Changes in and uncertainty surrounding U.S. trade policy could have a material adverse impact on our business, financial condition and results of operations
New U.S. tariffs and retaliatory measures from trading partners could negatively impact business operations.

Dropped

DroppedRisks Related to the Discovery, Development, and Commercialization of our Products and Product Candidates
In addition, we have a small number of clinical trial sites for certain clinical trials in the Middle East, including in Lebanon and Israel, that could be affected by the current armed conflict in the region
DroppedRisks Related to the Discovery, Development, and Commercialization of our Products and Product Candidates
We may need to further build our sales and marketing infrastructure, either directly or with third-party partners to commercialize PYRUKYND® in other indications or outside of the United States, or to commercialize any of our other product candidates for which we obtain marketing approval
DroppedRisks Related to the Discovery, Development, and Commercialization of our Products and Product Candidates
seek approval of generic versions of reference-listed drugs through submission of abbreviated new drug applications, or ANDAs, in the United States
DroppedRisks Related to Our Intellectual Property
consider the confidential information and know-how related to our cellular metabolism technology platform to be our primary intellectual property assets in this space. Unpatented proprietary technical information and know-how can be difficult to protect
DroppedRisks Related to Regulatory Approval of Our Product Candidates and Other Legal Compliance Matters
If we or our collaborators experience delays in obtaining approval or if we or they fail to obtain approval of our product candidates, the commercial prospects for our product candidates may be harmed and our ability to generate revenue will be materially impaired
Middle East armed conflict risks for clinical trials in Lebanon and Israel.
DroppedRisks Related to Regulatory Approval of Our Product Candidates and Other Legal Compliance Matters
If a product candidate is intended for the treatment of a serious or life-threatening disease or condition and the product candidate demonstrates the potential to address unmet medical needs for this disease or condition, the drug sponsor may apply for FDA fast track designation
DroppedRisks Related to Regulatory Approval of Our Product Candidates and Other Legal Compliance Matters
court finds, by a preponderance of the evidence, that the NDA holder did not have a legitimate business justification to delay providing the product or failed to comply with the court’s order
DroppedRisks Related to Our Common Stock and Other Matters
did not have a qualified ownership change since our last review as of December 31, 2023. Future ownership changes under Section 382 may limit the amount of net operating loss and tax credit carryforwards that we could potentially utilize to reduce future tax liabilities

Reworded

89% rewrittenRisks Related to Our Financial Position
We face challenges as a less diversified company
Updated to include AQVESME and specific pipeline status details for mitapivat in SCD and thalassemia.
Was: We face challenges as a smaller, less diversified company
89% rewrittenRisks Related to Our Intellectual Property
If we are unable to protect the confidentiality of our confidential information related to our proprietary platforms and technology, our business and competitive position could be harmed
Added specific references to the cellular metabolism technology platform and third-party agreements protecting know-how.
88% rewrittenRisks Related to the Discovery, Development, and Commercialization of our Products and Product Candidates
If we are unable to maintain sales and marketing capabilities or enter into agreements with third parties to sell and market our product candidates, we may not be successful in commercializing PYRUKYND®, AQVESME™ or any of our product candidates if they are approved
Updated to reflect the commercial launch and sales capabilities for AQVESME in alpha- or beta-thalassemia.
Was: If we are unable to maintain sales and marketing capabilities or enter into agreements with third parties to sell and market our product candidates, we may not be successful in commercializing PYRUKYND® or any of our product candidates if they are approved
88% rewrittenRisks Related to Regulatory Approval of Our Product Candidates and Other Legal Compliance Matters
We, or any collaborators, may not be able to obtain or maintain orphan drug designation or orphan drug exclusivity for our drug candidates and, even if we do, that exclusivity may not prevent the FDA or the EMA from approving competing drugs
Added conditions under which orphan drug exclusivity may be lost, such as material defects or insufficient product supply.
Was: We, or any collaborators, may not be able to obtain orphan drug designation or orphan drug exclusivity for our drug candidates and, even if we do, that exclusivity may not prevent the FDA or the EMA from approving competing drugs
88% rewrittenRisks Related to the Discovery, Development, and Commercialization of our Products and Product Candidates
If the FDA does not grant our products, if and when approved, appropriate periods of regulatory exclusivity before approving generic or follow-on versions of our products, the sales of our products could be adversely affected
Expanded to include detailed descriptions of ANDA requirements for generic competitors.
80% rewrittenRisks Related to Our Financial Position
Changes in tax laws or in their implementation or interpretation may adversely affect our business and financial condition
Added reference to the newly enacted One Big Beautiful Bill Act (OBBBA) of July 2025.
76% rewrittenRisks Related to Regulatory Approval of Our Product Candidates and Other Legal Compliance Matters
The CREATES Act exposes us to possible litigation and damages by competitors who may claim that we are not providing sufficient quantities of our approved products on commercially reasonable, market-based terms for testing in support of their ANDAs and 505(b)(2) applications
Clarified potential legal remedies and attorney fees under CREATES Act litigation.
Was: With the passage of the CREATES Act, we are exposed to possible litigation and damages by competitors who may claim that we are not providing sufficient quantities of our approved products on commercially reasonable, market-based terms for testing in support of their ANDAs and 505(b)(2) applications
71% rewrittenRisks Related to the Discovery, Development, and Commercialization of our Products and Product Candidates
If we do not successfully commercialize PYRUKYND®, AQVESME™ and other products for which we receive approval, our prospects may be substantially harmed
Updated with exact 2023-2025 net product revenues for PYRUKYND and the January 2026 launch of AQVESME.
Was: If we do not successfully commercialize PYRUKYND® and other products for which we receive approval, our prospects may be substantially harmed
70% rewrittenRisks Related to the Discovery, Development, and Commercialization of our Products and Product Candidates
Although we maintain product liability insurance coverage, it may not be adequate to cover all liabilities that we may incur
69% rewrittenRisks Related to Regulatory Approval of Our Product Candidates and Other Legal Compliance Matters
The prices of prescription pharmaceuticals have also been the subject of considerable discussion in the United States
62% rewrittenRisks Related to Our Common Stock and Other Matters
Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited
59% rewrittenRisks Related to the Discovery, Development, and Commercialization of our Products and Product Candidates
We or our collaborators may not be able to initiate, continue or complete clinical trials for our product candidates if we or they are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or analogous regulatory authorities outside the United States
58% rewrittenRisks Related to Regulatory Approval of Our Product Candidates and Other Legal Compliance Matters
Failure to obtain marketing approval in foreign jurisdictions would prevent our medicines from being marketed in such jurisdictions and any of our medicines that are approved for marketing in such jurisdictions will be subject to risk associated with foreign operations
Was: Failure to obtain marketing approval in foreign jurisdictions would prevent our medicines from being marketed in such jurisdictions and any of our medicines that are approved for marketing in such jurisdiction will be subject to risk associated with foreign operations
54% rewrittenRisks Related to the Discovery, Development, and Commercialization of our Products and Product Candidates
We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success
53% rewrittenRisks Related to Regulatory Approval of Our Product Candidates and Other Legal Compliance Matters
Current and future healthcare reform legislation may increase the difficulty and cost for us and any collaborators to commercialize our drug candidates
Was: Current and future healthcare reform legislation may increase the difficulty and cost for us and any collaborators to obtain reimbursement and commercialize our drug candidates
52% rewrittenRisks Related to the Discovery, Development, and Commercialization of our Products and Product Candidates
PYRUKYND®, AQVESME™ or any of our product candidates that may receive marketing approval in the future, may fail to achieve the degree of market acceptance by physicians, patients, healthcare payors and others in the medical community necessary for commercial success
Was: PYRUKYND®, or any of our product candidates that may receive marketing approval in the future, may fail to achieve the degree of market acceptance by physicians, patients, healthcare payors and others in the medical community necessary for commercial success
50% rewrittenRisks Related to Our Financial Position
We have historically incurred operating losses. We expect to incur losses in the future and may never achieve or maintain profitability
50% rewrittenRisks Related to Regulatory Approval of Our Product Candidates and Other Legal Compliance Matters
measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product or product candidates or additional pricing pressures
Was: healthcare products and services, which could result in reduced demand for our product or product candidates or additional pricing pressures
50% rewrittenRisks Related to the Discovery, Development, and Commercialization of our Products and Product Candidates
We may engage in in-licensing transactions or acquisitions that could disrupt our business, cause dilution to our stockholders or reduce our financial resources
46% rewrittenRisks Related to Our Dependence on Third Parties
We may depend on collaborations with third parties for the development and commercialization of our product candidates. If those collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates
43% rewrittenRisks Related to Our Dependence on Third Parties
If either we or any third parties on which we rely are adversely impacted by geopolitical events, delays may occur in our product development activities, which delays could have a material adverse impact on our business, financial condition and prospects
Was: If either we or any third parties on which we rely are adversely impacted by geopolitical events, rising global energy costs or energy shortages or rationing, delays may occur in our product development activities, which delays could have a material adverse impact on our business, financial condition and prospects
42% rewrittenRisks Related to Our Dependence on Third Parties
We contract with third parties for the manufacture of our product candidates for preclinical and clinical testing and for commercialization
36% rewrittenRisks Related to the Discovery, Development, and Commercialization of our Products and Product Candidates
We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do
35% rewrittenRisks Related to Our Financial Position
If our existing capital is insufficient to fund our operating expenses and capital expenditures, we will need to raise capital, and if we are unable to raise capital when needed, we would be forced to delay, reduce or eliminate our product development programs or commercialization efforts
29% rewrittenRisks Related to Our Intellectual Property
We may become involved in lawsuits to protect or enforce our patents and other intellectual property rights, which could be expensive, time consuming and unsuccessful
29% rewrittenRisks Related to the Discovery, Development, and Commercialization of our Products and Product Candidates
If we experience significant delays or an inability to successfully develop and commercialize PYRUKYND® and AQVESME™, our business would be materially harmed
Was: If we experience significant delays or an inability to successfully develop and commercialize PYRUKYND®, our business would be materially harmed
27% rewrittenRisks Related to Our Common Stock and Other Matters
The price of our common stock is volatile, which could result in substantial losses for purchasers of our common stock
Was: The price of our common stock is likely to be volatile, which could result in substantial losses for purchasers of our common stock
27% rewrittenRisks Related to the Discovery, Development, and Commercialization of our Products and Product Candidates
Results of preclinical studies and early clinical trials may not be predictive of results of later-stage clinical trials
24% rewrittenRisks Related to Regulatory Approval of Our Product Candidates and Other Legal Compliance Matters
PYRUKYND®, AQVESME™ or any product candidate that we commercialize may become subject to unfavorable pricing regulations and third-party reimbursement practices, which would harm our business
Was: PYRUKYND® or any product candidate that we commercialize may become subject to unfavorable pricing regulations and third-party reimbursement practices, which would harm our business

All 55 risk factors

Headings as the filing states them, in filing order.

Risks Related to the Discovery, Development, and Commercialization of our Products and Product Candidates

01If we do not successfully commercialize PYRUKYND®, AQVESME™ and other products for which we receive approval, our prospects may be substantially harmed71% rewritten
02If we experience significant delays or an inability to successfully develop and commercialize PYRUKYND® and AQVESME™, our business would be materially harmed29% rewritten
03PYRUKYND®, AQVESME™ or any of our product candidates that may receive marketing approval in the future, may fail to achieve the degree of market acceptance by physicians, patients, healthcare payors and others in the medical community necessary for commercial success52% rewritten
04If we are unable to maintain sales and marketing capabilities or enter into agreements with third parties to sell and market our product candidates, we may not be successful in commercializing PYRUKYND®, AQVESME™ or any of our product candidates if they are approved88% rewritten
05We may engage in in-licensing transactions or acquisitions that could disrupt our business, cause dilution to our stockholders or reduce our financial resources50% rewritten
06We or our collaborators may not be able to initiate, continue or complete clinical trials for our product candidates if we or they are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or analogous regulatory authorities outside the United States59% rewritten
07Ongoing or unanticipated geopolitical events in countries where we may to have clinical trial sites could also negatively impact our ability to initiate, enroll and retain patients in, and conduct clinical trialsNew
08Results of preclinical studies and early clinical trials may not be predictive of results of later-stage clinical trials27% rewritten
09Interim and preliminary data from clinical trials that we announce or publish from time to time may change as more patient data becomes available and are subject to audit and verification procedures that could result in material changes in the final data
10We conduct clinical trials at sites outside the United States. The FDA may not accept data from trials conducted in such locations, and the conduct of trials outside the United States could subject us to additional delays and expense
11We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success54% rewritten
12We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do36% rewritten
13If the FDA does not grant our products, if and when approved, appropriate periods of regulatory exclusivity before approving generic or follow-on versions of our products, the sales of our products could be adversely affected88% rewritten
14The FDA may not approve an ANDA or 505(b)(2) NDA until any applicable period of regulatory exclusivity for the reference-listed drug has expired, subject to certain exceptionsNew
15Product liability lawsuits against us or any collaborators could cause us or our collaborators to incur substantial liabilities and could limit commercialization of any medicines that we or they may develop
16Although we maintain product liability insurance coverage, it may not be adequate to cover all liabilities that we may incur70% rewritten
17eliminated entirely. We cannot guarantee that the measures we have taken to date, and actions we may take in the future, will be sufficient to prevent any cyber-attacks or security breachesNew

Risks Related to Our Financial Position

18We face challenges as a less diversified company89% rewritten
19product candidates, and unanticipated changes in applicable laws and regulations that may adversely affect the rare disease businessNew
20Raising additional capital may restrict our operations, require us to relinquish rights to our technologies or product candidates or cause dilution to our stockholders
21If our existing capital is insufficient to fund our operating expenses and capital expenditures, we will need to raise capital, and if we are unable to raise capital when needed, we would be forced to delay, reduce or eliminate our product development programs or commercialization efforts35% rewritten
22We have historically incurred operating losses. We expect to incur losses in the future and may never achieve or maintain profitability50% rewritten
23Changes in tax laws or in their implementation or interpretation may adversely affect our business and financial condition80% rewritten

Risks Related to Our Dependence on Third Parties

24We rely and expect to continue to rely on third parties to conduct our clinical trials and some aspects of our research and preclinical testing, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research or testing
25If either we or any third parties on which we rely are adversely impacted by geopolitical events, delays may occur in our product development activities, which delays could have a material adverse impact on our business, financial condition and prospects43% rewritten
26We contract with third parties for the manufacture of our product candidates for preclinical and clinical testing and for commercialization42% rewritten
27We may depend on collaborations with third parties for the development and commercialization of our product candidates. If those collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates46% rewritten

Risks Related to Our Intellectual Property

28We may become involved in lawsuits to protect or enforce our patents and other intellectual property rights, which could be expensive, time consuming and unsuccessful29% rewritten
29Third parties may initiate legal proceedings alleging that we or our collaborators are infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business
30We may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their former employers
31Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities
32If we are unable to protect the confidentiality of our confidential information related to our proprietary platforms and technology, our business and competitive position could be harmed89% rewritten

Risks Related to Regulatory Approval of Our Product Candidates and Other Legal Compliance Matters

33We may not be successful in obtaining FDA or EMA approval of our product candidates on a timely basis, or ever. We have limited experience in filing and supporting the applications necessary to gain marketing approvals and expect to rely on third-party CROs to assist us in this processNew
34Failure to obtain marketing approval in foreign jurisdictions would prevent our medicines from being marketed in such jurisdictions and any of our medicines that are approved for marketing in such jurisdictions will be subject to risk associated with foreign operations58% rewritten
35Fast track designation, priority review designation, PRIME designation or other expedited review designations or vouchers may not actually lead to a faster development or regulatory review or approval process, nor does it ensure approval of the product candidateNew
36We, or any collaborators, may not be able to obtain or maintain orphan drug designation or orphan drug exclusivity for our drug candidates and, even if we do, that exclusivity may not prevent the FDA or the EMA from approving competing drugs88% rewritten
37We do not know if, when, or how the FDA or Congress may reevaluate or change the orphan drug regulations and policies in the future, and it is uncertain how any changes might affect our business or if we will be adversely impactedNew
38Accordingly, if any of the foregoing developments and others impact the ability of the FDA to provide us with guidance or delay the FDA’s review and processing of our regulatory submissions, our business would be negatively impactedNew
39PYRUKYND®, AQVESME™ or any product candidate that we commercialize may become subject to unfavorable pricing regulations and third-party reimbursement practices, which would harm our business24% rewritten
40Current and future healthcare reform legislation may increase the difficulty and cost for us and any collaborators to commercialize our drug candidates53% rewritten
41The prices of prescription pharmaceuticals have also been the subject of considerable discussion in the United States69% rewritten
42measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product or product candidates or additional pricing pressures50% rewritten
43We are subject to U.S. and foreign export control, import, sanctions, anti-corruption and anti-money laundering laws with respect to our operations, and non-compliance with such laws can subject us to criminal and/or civil liability and harm our business
44Changes in and uncertainty surrounding U.S. trade policy could have a material adverse impact on our business, financial condition and results of operationsNew
45The CREATES Act exposes us to possible litigation and damages by competitors who may claim that we are not providing sufficient quantities of our approved products on commercially reasonable, market-based terms for testing in support of their ANDAs and 505(b)(2) applications76% rewritten
46If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business

Risks Related to Employee Matters and Managing Growth

47Our future success depends on our ability to retain our key executives and scientific leadership and to attract, retain and motivate qualified personnel
48Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business

Risks Related to Our Common Stock and Other Matters

49Provisions in our corporate charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management
50The price of our common stock is volatile, which could result in substantial losses for purchasers of our common stock27% rewritten
51Our executive officers, directors and principal stockholders maintain the ability to significantly influence all matters submitted to stockholders for approval
52Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited62% rewritten
53Our effective tax rate may fluctuate, and we may incur obligations in tax jurisdictions in excess of accrued amounts
54We incur costs as a result of operating as a public company, and our management is required to devote substantial time to compliance initiatives and corporate governance practices
55Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be the sole source of gain for our stockholders

Other Agios Pharmaceuticals 10-Ks

FY2024 10-K risk factors
54 risks
Commercializing PYRUKYND and advancing clinical candidates dominate this risk profile. Dependence on third-party manufacturers, clinical sites, and collaborative partners is critical. Intellectual property protection and regulatory pricing pressures heavily influence future viability.
Filed Feb 13, 2025

About this page

The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.